Osteosarcoma Metastatic clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
open to eligible people ages 5 years and up
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
at UCLA
Last updated: